Literature DB >> 15104897

Modification of alternative splicing by antisense therapeutics.

Ryszard Kole1, Marla Vacek, Tiffany Williams.   

Abstract

Alternative splicing allows the production of several different proteins from a single pre-mRNA, resulting in an increased diversity of proteins derived from a relatively limited number of transcribed genes. Although it is necessary for normal development, alternative splicing and its aberrations are also implicated in disease states from thalassemia and cancer to neurodegenerative disorders. Techniques that trick the splicing machinery to alter the splicing pathways can be of high therapeutic value. Antisense technology, used mostly for RNA downregulation, recently has been adapted to alter the splicing process. The promise of this approach is now being realized as a result of chemical modification of oligonucleotides and improvements in their delivery in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15104897     DOI: 10.1089/154545704322988067

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  13 in total

1.  Alternative splicing as a therapeutic target for human diseases.

Authors:  Kenneth J Dery; Veronica Gusti; Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Methods Mol Biol       Date:  2009

Review 2.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

3.  Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.

Authors:  Jonathan W Kotula; Elizabeth D Pratico; Xin Ming; Osamu Nakagawa; Rudolph L Juliano; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

Review 4.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

5.  Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.

Authors:  Nirmal K Singh; Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

6.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

Review 7.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12

8.  Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis.

Authors:  Md Rowshon Alam; Vidula Dixit; Hyunmin Kang; Zi-Bo Li; Xiaoyuan Chen; Joann Trejo; Michael Fisher; Rudy L Juliano
Journal:  Nucleic Acids Res       Date:  2008-03-26       Impact factor: 16.971

9.  Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.

Authors:  Gabriela D Ivanova; Andrey Arzumanov; Rachida Abes; Haifang Yin; Matthew J A Wood; Bernard Lebleu; Michael J Gait
Journal:  Nucleic Acids Res       Date:  2008-10-08       Impact factor: 16.971

10.  Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide.

Authors:  Saïd Abes; John J Turner; Gabriela D Ivanova; David Owen; Donna Williams; Andrey Arzumanov; Philippe Clair; Michael J Gait; Bernard Lebleu
Journal:  Nucleic Acids Res       Date:  2007-06-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.